Suggested remit: To appraise the clinical and cost effectiveness of adagrasib within its marketing authorisation for treating KRAS G12C mutation positive advanced NSCLC which has been previously treated, or is not suitable for treatment, with platinum based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Awaiting decision
|
| Process |
STA Standard
|
| ID number |
6339
|
Project Team
| Project lead |
Greg O'Toole |
Email enquiries
| External Assessment Group |
Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Stakeholders
| Companies sponsors |
Bristol Myers-Squibb (adagrasib) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Roy Castle Lung Cancer Foundation |
| Professional groups |
Association of Cancer Physicians |
| |
Association of Respiratory Nurse Specialists |
| |
British Thoracic Oncology Group |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
NHS Wales Joint Commissioning Committee |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| Relevant research groups |
Institute of Cancer Research |
| |
National Institute for Health & Care Research |
|
Date
|
Update
|
|
09 May 2025 - 02 June 2025
|
Draft guidance: 1 |
|
30 May 2025
|
Following a request from the company to review the appraisal timelines the second committee meeting will now no longer take place on Thursday 12 June. |
|
10 April 2025
|
Committee meeting |
|
06 September 2024
|
Invitation to participate |
|
09 July 2024 - 06 August 2024
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6339 |
|
09 July 2024
|
In progress. Scoping commenced. |
|
19 October 2023
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
|
26 June 2023
|
Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual